We’re experiencing issues with our datasets and search. We apologise for any inconvenience while we work to fix this.
SOTYKTU Bristol-Myers Squibb Australia Pty Ltd
Product name
SOTYKTU
Accepted date
Jul-2025
Active ingredients
deucravacitinib
Summary of proposed indication
Sotyktu (deucravacitinib) is proposed for the treatment of adult patients with active psoriatic arthritis, a form of inflammatory arthritis that affects some people with the skin condition psoriasis.
Application type
C (new indication)
Publication date
Jul-2025